ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREVENTION OR TREATMENT OF SYSTEMIC DISEASES IN CATS

A method is described for the prophylaxis or treatment of hypertension in a cat in need of such treatment. The method includes administration of a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to the cat, where the therapeutically effective amount of the sa...

Full description

Saved in:
Bibliographic Details
Main Authors ALBRECHT, Balazs, STARK, Marcus, TRAAS, Anne, ANKE, Sven, ZIMMERING, Tanja, LEHNER, Stefan, KLEY, Saskia
Format Patent
LanguageEnglish
French
Published 10.01.2019
Subjects
Online AccessGet full text

Cover

Loading…
Abstract A method is described for the prophylaxis or treatment of hypertension in a cat in need of such treatment. The method includes administration of a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to the cat, where the therapeutically effective amount of the sartan is administered in a daily dosage amount that is varied over a treatment period, the daily dosage amount of the sartan for a first period of time during the treatment period is 1.0 to 5.0 mg/kg of body weight, and the daily dosage amount of the sartan is decreased for a second period of time subsequent the first period of time during the treatment period. L'invention concerne une méthode de prévention ou de traitement de l'hypertension chez un chat nécessitant un tel traitement. La méthode comprend l'administration d'une quantité thérapeutiquement efficace d'un antagoniste du récepteur 1 (AT-1) de l'angiotensine II (sartan) au chat, la quantité thérapeutiquement efficace du sartan étant administrée dans une quantité de dosage quotidienne qui varie sur une période de traitement, la quantité de dosage quotidien du sartan pendant une première période pendant la période de traitement est de 1,0 à 5,0 mg/kg de poids corporel, et la quantité de dosage quotidien du sartan est réduite pendant une seconde période de temps après la première période de temps pendant la période de traitement.
AbstractList A method is described for the prophylaxis or treatment of hypertension in a cat in need of such treatment. The method includes administration of a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to the cat, where the therapeutically effective amount of the sartan is administered in a daily dosage amount that is varied over a treatment period, the daily dosage amount of the sartan for a first period of time during the treatment period is 1.0 to 5.0 mg/kg of body weight, and the daily dosage amount of the sartan is decreased for a second period of time subsequent the first period of time during the treatment period. L'invention concerne une méthode de prévention ou de traitement de l'hypertension chez un chat nécessitant un tel traitement. La méthode comprend l'administration d'une quantité thérapeutiquement efficace d'un antagoniste du récepteur 1 (AT-1) de l'angiotensine II (sartan) au chat, la quantité thérapeutiquement efficace du sartan étant administrée dans une quantité de dosage quotidienne qui varie sur une période de traitement, la quantité de dosage quotidien du sartan pendant une première période pendant la période de traitement est de 1,0 à 5,0 mg/kg de poids corporel, et la quantité de dosage quotidien du sartan est réduite pendant une seconde période de temps après la première période de temps pendant la période de traitement.
Author ANKE, Sven
STARK, Marcus
KLEY, Saskia
TRAAS, Anne
ALBRECHT, Balazs
LEHNER, Stefan
ZIMMERING, Tanja
Author_xml – fullname: ALBRECHT, Balazs
– fullname: STARK, Marcus
– fullname: TRAAS, Anne
– fullname: ANKE, Sven
– fullname: ZIMMERING, Tanja
– fullname: LEHNER, Stefan
– fullname: KLEY, Saskia
BookMark eNqNjLsKwkAQRbfQwtc_DFgLGy2i5bJOkikyKzuDYhWCrJUkgfj_GMEPsDqcw-Uuzazru7QwjeOSgiILMRBBRI8XDREcqysDkygUk2qFcIl4RVYKDN8S0Wk9OYQC5C6KNXk4k6ATFJjuvFNZm_mzfY1p8-PKbAtUX-3S0DdpHNpH6tK7uYW9zU7WHm2eu-zw3-oDjEY2BQ
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
DocumentTitleAlternate ANTAGONISTE DU RÉCEPTEUR DE L'ANGIOTENSINE II POUR LA PRÉVENTION OU LE TRAITEMENT DE MALADIES SYSTÉMIQUES CHEZ LES CHATS
ExternalDocumentID WO2019008077A1
GroupedDBID EVB
ID FETCH-epo_espacenet_WO2019008077A13
IEDL.DBID EVB
IngestDate Fri Oct 04 05:03:16 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
French
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_WO2019008077A13
Notes Application Number: WO2018EP68189
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20190110&DB=EPODOC&CC=WO&NR=2019008077A1
ParticipantIDs epo_espacenet_WO2019008077A1
PublicationCentury 2000
PublicationDate 20190110
PublicationDateYYYYMMDD 2019-01-10
PublicationDate_xml – month: 01
  year: 2019
  text: 20190110
  day: 10
PublicationDecade 2010
PublicationYear 2019
RelatedCompanies BOEHRINGER INGELHEIM VETMEDICA GMBH
RelatedCompanies_xml – name: BOEHRINGER INGELHEIM VETMEDICA GMBH
Score 3.1911006
Snippet A method is described for the prophylaxis or treatment of hypertension in a cat in need of such treatment. The method includes administration of a...
SourceID epo
SourceType Open Access Repository
SubjectTerms HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREVENTION OR TREATMENT OF SYSTEMIC DISEASES IN CATS
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20190110&DB=EPODOC&locale=&CC=WO&NR=2019008077A1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwEA9jivqmU_FjSkDpW7Fx_VgfhmRpulVYOto459Po10CQbriK_76Xuume9pbcwZEc3F1-l9wFofu54aRGt7DBxOe2bppFoieuSfTctpK8kztdI1HFySNhD1_M56k1baCPTS1M3Sf0u26OCBaVgb1Xtb9e_iexvPpt5eohfQfS4smXPU9bo2MV3Yihef0eH4deyDTGALdpIvrlwenIcShgpT11kFad9vmkr-pSlttBxT9G-2OQV1YnqFGULXTINn-vtdDBaH3lDcO19a1O0YyKQRBKLuJA4CDAEWd8LMMIUyHpIBRBLDGAOiyHHINmJ1yo_BNWlIhTqdr249DH8VsslfaxF8Scgj_FII5RGZ-hO59LNtRhpbM_xcxew-1tdc5Rs1yUxQXCJHc6JAVsl3dtM8-c9NGdAymzXOKmVkIuUXuXpKvd7Gt0pKYqEUGMNmpWn1_FDYTmKr2tNfoDWtuJ5g
link.rule.ids 230,309,786,891,25594,76903
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED-GivNNp-LH1IDSt2Lr-rE9DOnadK1u6WjjnE-lXTsQpBuu4r_vpW66p72FOziSH1wuv0vuAnA3U8xUaecGuvjMkDUtT-Sko6lyZuhJ1srMtpKI4uQhM7wX7WmiT2rwsa6FqfqEflfNEdGjpujvZbVfL_6TWE71tnJ5n76jaP7o8q4jrdixiG6qIjm9Lh0FTmBLto28TWLhrw5PR6ZpIVfaNZEUVmRp3BN1KYvNoOIewt4I7RXlEdTyogF1e_33WgP2h6srbxyuvG95DLHF-n7AKYt8RnyfhNSmIx6ExGLc6gfMjzhBUke4RwkiO6ZM5J-IkITU4qJtPwlcEr1FXKBPHD-iFu6nBM3ZFo9O4Nal3PZknGn8B0z8Gmwuq3UKO8W8yM-AqJnZUlPkdlnb0LKpmT50Ziia6h21k-qJeg7NbZYutqtvoO7x4SAe-Oz5Eg6ESiQlVKUJO-XnV36FYbpMryt0fwDy8YzQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=ANGIOTENSIN+II+RECEPTOR+ANTAGONIST+FOR+THE+PREVENTION+OR+TREATMENT+OF+SYSTEMIC+DISEASES+IN+CATS&rft.inventor=ALBRECHT%2C+Balazs&rft.inventor=STARK%2C+Marcus&rft.inventor=TRAAS%2C+Anne&rft.inventor=ANKE%2C+Sven&rft.inventor=ZIMMERING%2C+Tanja&rft.inventor=LEHNER%2C+Stefan&rft.inventor=KLEY%2C+Saskia&rft.date=2019-01-10&rft.externalDBID=A1&rft.externalDocID=WO2019008077A1